ArticleAnnals of surgical oncology2026
High Serum IgA Identifies Poor Responders to Immune Checkpoint Inhibitors in Patients with Unresectable Esophageal Squamous Cell Carcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ASO Author Reflections: Serum IgA as a Predictive Biomarker for Immunotherapy in Esophageal Squamous Cell Carcinoma.Annals of surgical oncology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have become a standard first-line treatment for unresectable esophageal squamous cell carcinoma (ESCC). However, a substantial proportion of patients have early disease progression. Reliable pretreatment biomarkers capable of predicting ICI efficacy are urgently needed. Immunoglobulin A (IgA) has been implicated in shaping an immunosuppressive tumor microenvironment, yet its clinical relevance in ESCC remains unclear.
methodsSerum IgA levels were measured in patients who had unresectable ESCC treated with first-line ICI-based therapy (n = 20) and compared with those in disease control subjects (non-ICI [n = 16] vs resectable ESCC [n = 26]) and healthy control subjects (n = 58). Associations between pretreatment serum IgA levels, survival times, and clinicopathologic variables were analyzed. The patients in each cohort were stratified into high- and low-IgA groups using cohort-specific median values.
resultsSerum IgA levels were significantly higher in all the ESCC patient groups than in the healthy control subjects. In the ICI-treated group, high pretreatment serum IgA was significantly associated with shorter progression-free survival (hazard ratio, 9.26; 95% confidence interval, 1.96-43.7; P = 0.005). No correlation between serum IgA and prognosis was observed in the non-ICI and resectable ESCC groups, indicating ICI-specific relevance. Pretreatment serum IgA did not correlate with clinicopathologic factors, including tumor markers and immune-related adverse events.
conclusionsHigh pretreatment serum IgA may serve as a novel, minimally invasive biomarker predicting poor response to ICI therapy in unresectable ESCC. Serum IgA assessment could support treatment decision-making and patient stratification in this era of expanding immunotherapy use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.